Watch List: Cerus Corporation, Turquoise Hill Resources, 8x8, Array Biopharma

Lakeway, NY -- (SBWIRE) -- 03/04/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Cerus Corporation (NASDAQ:CERS) stock jumped 11.25% to $3.66. The company, on Feb. 28, announced financial results for the fourth quarter and year ended December 31, 2012. Product revenue for the fourth quarter of 2012 was $10.5 million, a 6% increase over the fourth quarter of 2011. Net loss for the fourth quarter of 2012 was $1.7 million, or $0.07 per diluted share, compared to a net loss of $7.7 million, or $0.16 per diluted share, for the fourth quarter of 2011.

How Should Investors Trade CERS After The Recent Price movement? Find out Here

Turquoise Hill Resources Ltd (USA) (NYSE:TRQ) shares increased 11.01% and closed at $7.06 in the last trading session. The company, on Feb. 13, announced that it has signed a binding agreement with Sumeru Gold BV for the sale of the Company's 50% interest in Altynalmas Gold Ltd (Altynalmas) for a total cash consideration of $300 million. Completion of the proposed transaction is subject to customary closing conditions, including regulatory approvals from the Republic of Kazakhstan's competent authorities. The transaction is expected to close in the second quarter of 2013.

Is TRQ a Strong Buying Opportunity After The Recent Slump? Find out Here

8x8, Inc. (NASDAQ:EGHT) shares gained 10.08% to $6.66. The company announced that the Company will be presenting at three investor conferences in March 2013. 8x8 Chairman and CEO Bryan Martin will attend the Northland Capital Markets 2013 Technology Conference on Wednesday, March 13 at the Concierge Conference Center in New York where he will meet with small groups of investors throughout the day.

Is EGHT a Pump & Dump Stroy? Let’s Find out Here

Array Biopharma Inc (NASDAQ:ARRY) shares gained 9.77% to $4.27. In a press release recently Array BioPharma said that during 2013, the company expects to make substantial progress in generating data to inform registration study decisions for our wholly-owned hematology programs, ARRY-520 and ARRY-614. Array-invented MEK162 will be tested in a Phase 3 trial in NRAS melanoma which is scheduled to start in April 2013, as well as BRAF mutant melanoma later in 2013 (with Novartis (NVS)).

Is ARRY a Strong Buying Opportunity After The Recent Gain? Find out Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.